Table 2.

Tumor Response. Best tumor response is defined to be the best overall objective status determined by combining the patient’s status on target lesions, non-target lesions, and new disease. A confirmed tumor response is defined to be a CR or PR noted as the objective status on 2 consecutive evaluations at least 6 weeks apart. NE is defined as not evaluable either due to no measurement available post-baseline or there were not 2 consecutive evaluations at least 6 weeks apart.

Response Type	NTX-010 (n = 26)	Placebo (n = 24)	Overall (n = 50)
Best Response, n (%)
CR	1 (3.8)	2 (8.3)	3 (6.0)
PR	3 (11.5)	2 (8.3)	5 (10.0)
SD	9 (34.6)	4 (16.7)	13 (26.0)
PD	12 (46.2)	15 (62.5)	27 (54.0)
Non-CR/Non-PD	1 ( 3.8)	0 ( 0.0)	1 ( 2.0)
NE*	0 (0.0)	1 (4.2)	1 (2.0)
Confirmed Response, n (%)
CR	0 (0.0)	2 (8.3)	2 (4.0)
PR	1 (3.8)	2 (8.3)	3 (6.0)
SD	4 (15.4)	2 (8.3)	6 (12.0)
PD	19 (73.1)	18 (75.0)	37 (74.0)
Non-CR/Non-PD	1 ( 3.8)	0 ( 0.0)	1 ( 2.0)
NE*	1 (3.8)	0 (0.0)	1 (2.0)